Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary.
Szabo BG, Lenart KS, Petrik B, Gaspar Z, Kiss-Dala N, Szlavik J, Valyi-Nagy I, Lakatos B; Saint Ladislaus COVID-19 Collaborative. Szabo BG, et al. Among authors: lakatos b. Geroscience. 2021 Oct;43(5):2205-2213. doi: 10.1007/s11357-021-00452-9. Epub 2021 Sep 3. Geroscience. 2021. PMID: 34476717 Free PMC article.
Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study.
Lakatos B, Szabó BG, Bobek I, Kiss-Dala N, Gáspár Z, Riczu A, Petrik B, Farkas BF, Sebestyén G, Gopcsa L, Bekő G, Sinkó J, Reményi P, Szlávik J, Mathiász D, Vályi-Nagy I. Lakatos B, et al. Int J Infect Dis. 2022 Dec;125:233-240. doi: 10.1016/j.ijid.2022.10.037. Epub 2022 Oct 31. Int J Infect Dis. 2022. PMID: 36328291 Free PMC article.
Outcomes of high-risk adult outpatients treated with early remdesivir therapy during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron era: experiences from the national centre of Hungary.
Gáspár Z, Szabó BG, Ábrahám A, Várnai Z, Kiss-Dala N, Szlávik J, Sinkó J, Vályi-Nagy I, Lakatos B. Gáspár Z, et al. Among authors: lakatos b. Naunyn Schmiedebergs Arch Pharmacol. 2023 Aug;396(8):1857-1862. doi: 10.1007/s00210-023-02456-y. Epub 2023 Mar 9. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 36892627 Free PMC article.
Clinical and Microbiological Outcomes and Follow-Up of Secondary Bacterial and Fungal Infections among Critically Ill COVID-19 Adult Patients Treated with and without Immunomodulation: A Prospective Cohort Study.
Szabó BG, Czél E, Nagy I, Korózs D, Petrik B, Marosi B, Gáspár Z, Rajmon M, Di Giovanni M, Vályi-Nagy I, Sinkó J, Lakatos B, Bobek I. Szabó BG, et al. Among authors: lakatos b. Antibiotics (Basel). 2023 Jul 17;12(7):1196. doi: 10.3390/antibiotics12071196. Antibiotics (Basel). 2023. PMID: 37508292 Free PMC article.
Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated with baricitinib: a comparative study from the national centre of Hungary.
Gáspár Z, Szabó BG, Andrikovics H, Ceglédi A, Rajmon M, Ábrahám A, Várnai Z, Kiss-Dala N, Szlávik J, Sinkó J, Vályi-Nagy I, Lakatos B. Gáspár Z, et al. Among authors: lakatos b. Geroscience. 2024 Jun;46(3):2863-2877. doi: 10.1007/s11357-024-01099-y. Epub 2024 Feb 17. Geroscience. 2024. PMID: 38367195 Free PMC article.
Characteristics of Enterococcus species bloodstream infections among adults with and without onco-hematological malignancies: Experiences from the national center of Hungary.
Marosi B, Kádár B, Bruzsa A, Kocsis L, Kamotsay K, Sinkó J, Szabó BG, Lakatos B. Marosi B, et al. Among authors: lakatos b. Eur J Microbiol Immunol (Bp). 2024 Mar 27;14(2):134-142. doi: 10.1556/1886.2024.00011. Print 2024 May 14. Eur J Microbiol Immunol (Bp). 2024. PMID: 38536399 Free PMC article.
210 results